TranslateEupraxia Pharmaceuticals Inc
EPRX · TO
CA$9.18CAD
-0.25 (-2.65%)
Press Releases
Market Cap
CA$611.96 M
EPS
-CA$1.43
About
Eupraxia Pharmaceuticals Inc (TO:EPRX) — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 17 2026
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Mar 13 2026
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
Feb 20 2026
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
Feb 20 2026
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
Feb 19 2026
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
Recent Videos
“Turning EOE Into a Once-A-Year Appointment" w/ Eupraxia (NASDAQ: EPRX) CEO James A. Helliwell M.D.
Apr 01, 2026
Eupraxia Pharma: My View on Their Growth & Dilution Risks
Mar 13, 2026
How New Drug Delivery Methods Are Changing Lives: Eupraxia’s Innovations Explained -James Helliwell
Oct 14, 2025
Investing in Tomorrow's Giants: Palantir, AppLovin, Carvana, and Eupraxia Pharmaceuticals
Sep 23, 2025
Financials
Revenue
CA$0
Market Cap
CA$611.96 M
EPS
-1.43
